Literature DB >> 14616431

Bioavailability of dexmedetomidine after extravascular doses in healthy subjects.

Markku Anttila1, Jani Penttilä, Antti Helminen, Lauri Vuorilehto, Harry Scheinin.   

Abstract

AIM: To determine the absolute bioavailability of extravascularly administered dexmedetomidine, a novel a2-adrenoceptor agonist, in healthy subjects.
METHODS: Single 2 microg x kg-1 doses of dexmedetomidine were given intravenously, intramuscularly, perorally and buccally (where the solution is not swallowed) to 12 healthy male subjects. The drug concentration-time data were analysed using linear one-compartment (buccal and peroral data), or two-compartment modelling (intravenous data), or noncompartmental methods (intramuscular data).
RESULTS: Mean (95% CI) absolute bioavailability after peroral, buccal and intramuscular administration was 16% (12-20%), 82% (73-92%) and 104% (96-112%), respectively.
CONCLUSION: Dexmedetomidine is well absorbed systemically through the oral mucosa, and therefore buccal dosing may provide an effective, noninvasive route to administer the drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616431      PMCID: PMC1884292          DOI: 10.1046/j.1365-2125.2003.01944.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  Dexmedetomidine: a promising agent for anesthesia and perioperative care.

Authors:  R Ben-Abraham; D Ogorek; A A Weinbroum
Journal:  Isr Med Assoc J       Date:  2000-10       Impact factor: 0.892

2.  Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.

Authors:  V P Shah; K K Midha; S Dighe; I J McGilveray; J P Skelly; A Yacobi; T Layloff; C T Viswanathan; C E Cook; R D McDowall
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Oct-Dec       Impact factor: 2.441

3.  Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs.

Authors:  E Kuusela; M Raekallio; M Anttila; I Falck; S Mölsä; O Vainio
Journal:  J Vet Pharmacol Ther       Date:  2000-02       Impact factor: 1.786

4.  Influence of cardiac output on dexmedetomidine pharmacokinetics.

Authors:  S Dutta; R Lal; M D Karol; T Cohen; T Ebert
Journal:  J Pharm Sci       Date:  2000-04       Impact factor: 3.534

5.  The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment.

Authors:  A M De Wolf; R J Fragen; M J Avram; P C Fitzgerald; F Rahimi-Danesh
Journal:  Anesth Analg       Date:  2001-11       Impact factor: 5.108

Review 6.  Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit.

Authors:  G Angelini; J T Ketzler; D B Coursin
Journal:  Crit Care Clin       Date:  2001-10       Impact factor: 3.598

7.  Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine.

Authors:  H Scheinin; S Karhuvaara; K T Olkkola; A Kallio; M Anttila; L Vuorilehto; M Scheinin
Journal:  Clin Pharmacol Ther       Date:  1992-11       Impact factor: 6.875

8.  The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers.

Authors:  J B Dyck; M Maze; C Haack; L Vuorilehto; S L Shafer
Journal:  Anesthesiology       Date:  1993-05       Impact factor: 7.892

9.  Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine.

Authors:  K T Kivistö; A Kallio; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Intramuscular dexmedetomidine as premedication for general anesthesia. A comparative multicenter study.

Authors:  H Scheinin; M L Jaakola; S Sjövall; T Ali-Melkkilä; S Kaukinen; J Turunen; J Kanto
Journal:  Anesthesiology       Date:  1993-06       Impact factor: 7.892

View more
  58 in total

1.  Buccal and intranasal lorazepam clinical pharmacokinetics: can it adequately compete with intravenous lorazepam in pediatric care patients?

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2012-02-25       Impact factor: 2.953

Review 2.  Options and Considerations for Procedural Sedation in Pediatric Imaging.

Authors:  John W Berkenbosch
Journal:  Paediatr Drugs       Date:  2015-10       Impact factor: 3.022

3.  Buccal administration of dexmedetomidine as a preanesthetic in children.

Authors:  Yoshio Sakurai; Toru Obata; Akio Odaka; Katsuo Terui; Masanori Tamura; Hideki Miyao
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

4.  Dexmedetomidine in current anaesthesia practice- a review.

Authors:  Shagufta Naaz; Erum Ozair
Journal:  J Clin Diagn Res       Date:  2014-10-20

5.  Comment on: "Intranasal Dexmedetomidine for Procedural Sedation in Children, a Suitable Alternative to Chloral Hydrate".

Authors:  M S Raghuraman
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

6.  Effectiveness of nebulized dexmedetomidine for treatment of post-dural puncture headache in parturients undergoing elective cesarean section under spinal anesthesia: a randomized controlled study.

Authors:  Sherif M S Mowafy; Shereen E Abd Ellatif
Journal:  J Anesth       Date:  2021-05-16       Impact factor: 2.078

7.  Bioavailability of dexmedetomidine after intranasal administration.

Authors:  Timo Iirola; Sanna Vilo; Tuula Manner; Riku Aantaa; Maria Lahtinen; Mika Scheinin; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2011-02-12       Impact factor: 2.953

8.  Pain management following myringotomy and tube placement: intranasal dexmedetomidine versus intranasal fentanyl.

Authors:  Elisabeth Dewhirst; Gina Fedel; Vidya Raman; Julie Rice; N'Diris Barry; Kris R Jatana; Charles Elmaraghy; Meredith Merz; Joseph D Tobias
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2014-04-16       Impact factor: 1.675

Review 9.  [Dexmedetomidine. Pharmacokinetics and pharmacodynamics].

Authors:  H Ihmsen; T I Saari
Journal:  Anaesthesist       Date:  2012-12       Impact factor: 1.041

10.  A Pharmacokinetic and Pharmacodynamic Study of Oral Dexmedetomidine.

Authors:  Shubham Chamadia; Juan C Pedemonte; Lauren E Hobbs; Hao Deng; Sarah Nguyen; Luis I Cortinez; Oluwaseun Akeju
Journal:  Anesthesiology       Date:  2020-12-01       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.